InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$232.65

2026-10-16

Market Cap

$34.4B

Volume

1.5M

52-Wk High

$240.99

52-Wk Low

$138.00

Trailing PE

41.0

P/S

3.46

Gross Margin

67.7%

Net Margin

8.4%

ROE

5%

ROIC

4%

Piotroski

4/9

Altman Z

3.0

1-Yr Return

+63.5%

5-Yr Return

+0.6%

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNASDAQMarket Cap$34.4BEmployees7,500 (SEC-filed)CEOChristopher A. ViehbacherIPO1991-09-17CountryUS

225 Binney Street, Cambridge, MA 02142 · Tel 617 679 2000 · biogen.com

INSIDERSTREET SCORE49 / 100Street mean $250.53 (15 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$0M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · BIIB +63.5% · S&P 500 +15.9% · spread +47.7pp

7 Years vs S&P 500 · BIIB +0.6% · S&P 500 +189.9% · spread -189.3pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE49of 100

Score Breakdown

Profitability	33/100
Growth	20/100
Momentum	55/100
Quality	63/100
Earnings Quality	68/100
Balance Sheet	52/100
Value	38/100
Risk (safety)	65/100
Overall	48.5/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
BMY	68
PFE	46
GILD	44
AMGN	67
AZN	71
NVS	65
BIIB	49

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 70 in 25 Q2, latest 49 — -21 since. Dropped below the 55 line in 26 Q2, at 49. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY49 / 100IS Score 48.5 / 100 · -21.5 from peak of 70

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 84 / 100 · Power +69 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 49, price structure 84 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 48.5	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 69 → 53 → 63 → 49	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,044 → now 1,044	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)12 buys2026-09-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)1238 up / 1063 downnet +175 funds

Institutions Added (13F)35managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,044 · latest 1,044 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,044	143.5M	$30.6B	97.2%
2026 Q1	1,009	135.0M	$24.1B	91.4%
2025 Q4	1,001	139.7M	$23.9B	94.6%
2025 Q3	906	131.3M	$17.9B	88.9%
2025 Q2	865	130.2M	$15.9B	88.2%
2025 Q1	880	130.1M	$17.1B	88.0%
2024 Q4	877	132.4M	$19.2B	89.6%
2024 Q3	917	129.8M	$23.8B	87.9%
2024 Q2	940	129.0M	$27.8B	87.3%
2024 Q1	949	129.7M	$25.9B	87.8%
2023 Q4	997	128.7M	$30.9B	87.1%
2023 Q3	954	125.0M	$30.3B	84.6%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Godbout Sean	Chief Accounting Officer	2026-10-02	EXERCISE	27	—	1,467
Godbout Sean	Chief Accounting Officer	2026-10-02	TAX W/H	8	$0.00M	1,459
Godbout Sean	Chief Accounting Officer	2026-10-02	EXERCISE	27	—	0
Godbout Sean	Chief Accounting Officer	2026-10-01	A-Award	985	—	985
Parini Michael	Chief Legal Officer	2026-09-01	A-Award	7,405	—	7,405
Minor Lloyd	director	2026-08-04	SELL	593	$0.12M	2,689
Minor Lloyd	director	2026-08-03	SELL	593	$0.12M	3,282
Pangalos Menelas N	director	2026-06-09	EXERCISE	2,370	—	2,370

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	2	1,186	$0.2M	Counted
M — Exercises (paired A/D)	4	3,517	—	None — mechanics
F — Tax withholding	3	517	$0.1M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$0.2M2 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-04	Minor Lloyd	593	$0.1M
2026-08-03	Minor Lloyd	593	$0.1M
2026-02-09	Singhal Priya	2,660	$0.5M
2026-02-02	Singhal Priya	748	$0.1M
Trailing 12 mo	5 filings	5,111	$1M

Filed	Form	Reporting person	% of class	Shares
2026-08-06	SCHEDULE 13G/A	Abigail P. Johnson	12.40%	18.3M sh
2026-06-05	SCHEDULE 13G/A	Abigail P. Johnson	11.30%	16.7M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.48%	11.0M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Maria Elvira Salazar	House	SELL	$1,001 - $15,000	2026-09-24	2026-10-08
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-11	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
Susan M. Collins	Senate	BUY	$15,001 - $50,000	2022-11-03	2022-12-16
Sheldon Whitehouse	Senate	SELL	$1,001 - $15,000	2019-03-22	2019-04-17
Sheldon Whitehouse	Senate	SELL	$1,001 - $15,000	2019-03-22	2019-04-16

House 12-Mo22 trades14 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,009

13F Shares135M91.4% of shares out

New / Closed138 / 107positions, QoQ

Increased / Reduced401 / 287positions, QoQ

Put/Call (13F)0.94option positions

Free Float99.2%147M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Artemis Investment Management Llp	581,774	$131M
Beau Ventures, Llc	100,000	$23M
Wealth Enhancement Advisory Servic	65,649	$9M
Banque Pictet & Cie Sa	64,875	$15M
Gateway Investment Advisers Llc	51,369	$12M
Contravisory Investment Management	43,849	$10M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VPMAX	1.9%	$1.8B
VPMCX	1.9%	$1.8B
VITSX	0.0%	$1.1B
VSMPX	0.0%	$1.1B
VTI	0.0%	$1.1B
VTSAX	0.0%	$1.1B

13F Filers Holding BIIB — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session78.2%2026-10-15

20-Day Avg61.1%50-day 60.0%

TrendRising20d vs 50d

By Market CenterQ: 78% · N: 83% · B: 66%latest session

Weekly Notional ($B)

Where BIIB Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.6M	34 sh
Ubsa Ubs Ats	1.2M	40 sh
Sgmt Sigma X2	1.2M	33 sh
Mlix Instinct X	0.7M	42 sh
Ebxl Level Ats	0.7M	21 sh
Mstx Ms Trajectory Cross (Ats-1)	0.7M	27 sh

Where a dollar of Biogen Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
Non-US	$3.6B	60%
UNITED STATES	$2.4B	40%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

BIIB (live moat model)Peer median: BMY · PFE · GILD · AMGN · AZN

Component scores from the live moat model. Peer median illustrative.

Moat score 38/100 — None; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Christopher A. Viehbacher	President, Chief Executive Officer & Director
Nicole Murphy	Executive Vice President and Head of Pharmaceutical Operations & Technology
Priya Singhal	Executive Vice President & Head of Development
Robin C. Kramer	Executive Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+21.7%

Next Report2026-10-28

Income Quality6.89OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	-18.3%	-7.4%	-3.3%	-1.6%	+1.4%
Gross profit	-23.8%	-11.0%	-7.5%	+0.9%	-6.1%
Operating income	-39.2%	+3.5%	-27.4%	+18.7%	-24.6%
Net income	-61.1%	+95.8%	-61.9%	+40.6%	-20.8%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	11.0	10.2	9.8	9.7	9.8
Cost of revenue	2.1	2.3	2.5	2.3	2.9
Gross profit	8.9	7.9	7.3	7.4	6.9
R&D expense	3.4	2.6	2.7	2.5	2.0
SG&A expense	2.7	2.4	2.5	2.4	2.4
Operating income	2.8	2.9	2.1	2.5	1.9
EBITDA	3.9	3.5	2.4	3.0	3.1
D&A	0.5	0.5	0.5	0.7	0.9
Pretax income	1.8	3.6	1.3	1.9	1.4
Income tax	0.1	0.6	0.1	0.3	0.1
Net income	1.6	3.0	1.2	1.6	1.3
Diluted EPS ($)	10.40	20.87	7.97	11.19	8.83
Diluted shares (M)	150	146	146	146	147

Operating CF$2B

CapEx$0B

Free cash flow$2B

SBC$0B

Buybacks$0B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	3.4	1.0	2.4	3.0
ST investments	1.5	0.0	0.0	0.8
Receivables (net)	2.1	2.1	1.9	1.9
Total current assets	9.8	6.9	7.5	9.0
PP&E (net)	3.7	3.7	3.5	3.3
Goodwill + intangibles	7.6	14.6	16.2	15.7
Total assets	24.6	26.8	28.0	29.4
Accounts payable	0.5	0.4	0.4	0.4
Short-term debt	0.0	0.2	1.7	0.1
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	3.3	3.4	5.5	3.3
Long-term debt	6.3	6.8	4.5	6.6
Total liabilities	11.2	12.0	11.3	11.2
Shareholders' equity	13.4	14.8	16.7	18.3

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	3.0	1.2	1.6	1.3
D&A	0.5	0.5	0.7	0.8
Stock-based compensation	0.3	0.3	0.3	0.3
Working capital change	(0.9)	(0.6)	(0.2)	(1.1)
Operating cash flow	1.4	1.5	2.9	2.2
Capital expenditures	(0.2)	(0.3)	(0.4)	(0.2)
Investing cash flow	1.6	(4.1)	(0.8)	(1.4)
Buybacks	(0.8)	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	(1.0)	0.2	(0.7)	(0.0)
Financing cash flow	(1.8)	0.1	(0.7)	(0.3)
Free cash flow	1.1	1.2	2.5	2.1

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	14.4%	25.1%	8.2%	10.4%	7.4%	5%
ROA	6.4%	12.6%	4.5%	5.9%	4.5%	2.6%
ROIC	18.2%	15.7%	8.9%	8.8%	8.1%	4.3%
Gross margin	80.8%	77.6%	74.2%	76.1%	70.5%	67.7%
Operating margin	25.4%	28.4%	21.3%	25.7%	19.1%	12.8%
Net margin	14.2%	29.9%	11.8%	16.9%	13.2%	8.4%
EBITDA margin	35.7%	34.8%	24.2%	31.0%	31.6%	19.7%
FCF margin	30.5%	11.2%	12.6%	26.0%	21.8%	—
VALUATION
P/E	22.74	13.20	32.47	13.69	19.96	41.0
P/B	3.25	3.00	2.55	1.34	1.41	1.8
P/S	3.22	3.95	3.83	2.31	2.63	3.46
P/FCF	10.58	35.24	30.39	8.88	12.07	11.6
EV/EBITDA	11.61	11.86	18.51	8.43	9.60	21.2
EV/Revenue	3.57	4.12	4.47	2.75	2.95	4.2
Earnings yield	4.4%	7.6%	3.1%	7.3%	5.0%	2.43%
FCF yield	9.5%	2.8%	3.3%	11.3%	8.3%	8.64%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.83	2.99	2.00	1.35	2.68	1.87
Quick ratio	1.51	2.58	1.26	0.90	2.03	1.26
Debt / equity	0.70	0.49	0.50	0.40	0.38	0.44
Debt / assets	31.8%	26.9%	27.3%	23.6%	23.6%	26.0%
Net debt / EBITDA	1.13	0.49	2.65	1.35	1.04	3.61
Interest coverage	11.39	12.24	7.62	9.91	7.77	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.45	0.42	0.38	0.35	0.34	0.31
Receivables turnover	5.12	4.96	4.64	4.88	5.25	5.3
DSO (days)	71	74	79	75	69	69
DPO (days)	90	87	64	56	54	46
Cash conversion cycle	190	203	293	359	307	294
GROWTH (YoY)
Revenue growth	-18.3%	-7.4%	-3.3%	-1.6%	1.4%	—
Net income growth	-61.1%	95.8%	-61.9%	40.6%	-20.8%	—
EPS growth	-59.4%	98.9%	-62.0%	40.2%	-21.1%	—
FCF growth	-11.7%	-65.9%	8.7%	102.7%	-15.0%	—
PER SHARE ($)
EPS (diluted, TTM)	10.55	20.98	7.97	11.17	8.82	5.65
Book value / share	73.87	92.27	101.57	114.41	124.45	127.61
Revenue / share	74.45	70.06	67.51	66.23	66.88	67.35
FCF / share	22.68	7.86	8.52	17.22	14.58	20.10
Cash / share	25.78	33.70	7.21	16.26	26.01	8.70
SHAREHOLDER RETURN & SCORES
Buyback yield	5.1%	1.9%	0.0%	0.0%	0.0%	—
Altman Z-Score	3.50	4.24	3.55	2.86	3.16	3.0
Piotroski F-Score	4	7	3	6	6	4/9
Beneish M-Score	-3.04	-2.10	-2.37	-2.80	-2.65	-2.74

Model	Score	Zone	Note
Piotroski F-Score	4 / 9	Middling
Altman Z-Score	3.0	Safe (>2.99)	Grey
Income quality	6.89	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.74	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.98
Interest burden	0.77
Operating margin	11.2%
Asset turnover	0.33×
Financial leverage	1.66×
= ROE	5%

Growth Quality (live)	Value
Revenue stability	0.61
Earnings stability	0.47
Earnings persistence	0.82
Revenue CAGR 3y	-0.1%
EPS CAGR 3y	-32.6%
FCF CAGR 3y	38.1%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.00%

Dividend Yield0.00%none paid

Total Shareholder Return-0.03%cash yield

SBC / Revenue1.4%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
BMY	$122.1B	13.2	47%	25.6%	+3.1%	8/9	+43.8%
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	+24.2%
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	+33.4%
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	+50.3%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	—
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	—
OGN	$3.6B	17.4	24%	6.9%	-2.5%	5/9	—
CNC	$34.2B	-6.7	-20%	2.5%	+8.7%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

49 Analysts

Str Sell (0)Sell (1)Hold (16)Buy (32)Str Buy (0)

Mean Target (qtr)$250.5315 targets

Target vs. Price+7.7%last-quarter mean

Next Report2026-10-28street $2.00

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$10.45B	$10.59B / $10.07B	$12.42	$15.41 / $10.80	20
FY2027	$10.67B	$11.16B / $10.11B	$16.50	$19.71 / $11.54	20
FY2028	$10.99B	$11.66B / $10.10B	$18.62	$25.24 / $13.46	11

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$248.67	+6.9%	3
Last Quarter	$250.53	+7.7%	15
Last Year	$218.95	-5.9%	58
All Time	$246.60	+6.0%	149

Rolling mean of published targets vs. last close $232.65. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

5/5

ROE

3/5

ROA

4/5

Debt/Eq

2/5

P/E

1/5

P/B

4/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

BIIB +63.5% vs S&P 500 +15.9% — spread +47.7pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$226.11	+6.54	+2.89%	Above
SMA 50	$219.71	+12.94	+5.89%	Above
SMA 200	$197.83	+34.82	+17.60%	Above
EMA 9	$229.27	+3.38	+1.47%	Above
EMA 21	$225.73	+6.92	+3.07%	Above
EMA 50	$219.90	+12.75	+5.80%	Above
EMA 200	$199.02	+33.63	+16.90%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6920 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%69

Volatility 10%83

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago45%+55 pts since

12 Weeks Ago36%+64 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$226.11

Price vs SMA 50$219.71

Price vs SMA 200$197.83

EMA 9/21 Cross229.3/225.7

SMA 50/200Golden

ADX DirectionADX 23

Supertrend$218

Parabolic SAR$218

SMA Slope0.860

RSI61.5

Stochastic K/D74/70

StochRSI K/D92/89

Williams %R-33

CCI140

TSI vs Signal18.5

CMO22.9

ROC5.81%

OBV SignalDistrib

Chaikin MF-0.150

MFI50

Force Index1M

Elder Ray Bull11.32

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 70

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$237.19 / $239.15 / $242.96	S1 / S2	$233.38 / $231.42
Bollinger (20,2)	$217.22 – $235.00	Squeeze	ON
52-wk range	$138.00 – $240.99	Off 52-wk high	-3.5%
ATR (14)	$6.34 (2.7%)	Historical vol	22.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+1.8%Jan60%

-1.3%Feb40%

-0.6%Mar48%

+1.1%Apr40%

+1.9%May60%

+0.5%Jun50%

+1.6%Jul65%

+0.3%Aug60%

+1.7%Sep60%

+0.2%Oct40%

+2.4%Nov65%

-0.1%Dec45%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	BIIB	S&P 500
Weekly volatility (σ, 1y)	3.56%	1.83%
Best / worst week (1y)	+9.6% / -7.3%	—
Max drawdown (5y, monthly)	-68.8%	—
1-week VaR (95%)	-5.3%	—
Beta (5y)	0.17	1.00

BIIB EQUITY WEATHER (LIVE)PARTLY CLOUDY · +23

Trend+44

Momentum+41

Volume+35

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 256 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+22.8+32.4 vs industry

Trend+44.2+48.3 vs industry

Momentum+40.7+30.8 vs industry

Volume+34.6+18.0 vs industry

Reading	BIIB	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	+22.8	-9.5	-24.0	-20.5
Trend	+44.2	-4.1	-25.6	-21.3
Momentum	+40.7	+9.9	-28.5	-15.8
Volume	+34.6	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Christopher A. Viehbacher President and Chie	$23.6M	91% equity+incentive
Susan H. Alexander Executive Vice President,	$8.1M	85% equity+incentive
Nicole C. Murphy Head of Pharmaceutical Oper	$7.6M	86% equity+incentive
Priya A. Singhal Head of Development	$7.6M	86% equity+incentive
Robin C. Kramer Executive Vice President and	$5.8M	85% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	70
Social	64
Governance	74
Composite ESG	69

Composite ESG Trend

Filed	8-K contents	Items
2026-07-29	Earnings Release; Exhibits	2.02,9.01
2026-07-01	Earnings Release	2.02
2026-06-10	Shareholder Vote	5.07
2026-06-10	Exhibits	9.01
2026-05-14	Material Agreement; Acquisition/Disposition; Financial Obligation; Reg	1.01,2.01,2.03,7.01,9.01
2026-04-29	Earnings Release; Exhibits	2.02,9.01
2026-04-06	Earnings Release	2.02
2026-03-31	Material Agreement; Other Events; Exhibits	1.01,8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-07-22 to 2026-04-29
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	96 rows · 2002 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-06-09 to 2026-10-02
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-03-26 to 2026-08-06
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Biogen Inc. (BIIB)

Institutions holding — 12 quarters

Biogen Inc. (BIIB)

Monthly Net Insider Flow (000 shares)

Signal Summary

Biogen Inc. (BIIB)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding BIIB — quarterly

Institutional Put/Call — quarterly

Biogen Inc. (BIIB)

Where BIIB Trades in the Dark

Biogen Inc. (BIIB)

3.8 · Employees (SEC filings)

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Balance Sheet — Full

Cash Flow Statement — Full

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Street Price Target — Trajectory

Third-Party Composite Rating

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Family Scores (site weights)

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)

Biogen Inc. (BIIB)